About: Occurrence, analysis of fine specificity and biological role of serum autoantibodies against calreticulin and tissue transglutaminase in patients with oncological diseases and selected risk groups

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Occurrence, analysis of fine specificity and biological role of serum autoantibodies against calreticulin and tissue transglutaminase in patients with oncological diseases and selected risk groups Goto Sponge Distinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Projekt, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/domain/vavai/Projekt
Description	Příčinou vysoké mortality pacientů s nádory pankreatu (PT) je diagnostikování obvykle již pokročilých, neléčitelných stádií onemocnění. Sérologický znak časných stádií PT chybí. U několika pacientů s PT byly však prokázány autoprotilátky proti kalretikulinu (CRT) kombinací 2D-PAGE a imunoblotu. Vyvinuli jsme ELISA test využívající lidský rekombinantní CRT jako antigen a prokázali zvýšené hladiny protilátek IgA izotypu v sérech 60% a IgG v sérech 80% pacientů s PT. Několik pacientů vykazovalo i zvýšené hladiny IgA protilátek proti tkáňové transglutamináze (tTG) a gliadinu – sérologickým znakům celiakie. V tomto projektu budeme: a) měřit hladiny IgA a IgG protilátek proti CRT a gliadinu a IgA protilátek proti tTG v sérech pacientů s PT a jinými malignitami a pacientů rizikových skupin, b) charakterizovat specificitu těchto protilátek, c) studovat mechanismy vedoucí ke vzniku protilátek proti CRT a tTG u onkologických pacientů, d) analyzovat vliv anti-CRT protilátek na nádorové buňky. (cs) The mortality of patients with pancreatic tumors (PT) is frequently high due to late diagnosis. Appropriate serological marker for early stages of PT is still missing. Recently, serum autoantibodies (Ab) to calreticulin (CRT) have been found in some patients with PT using a combination of 2D-PAGE and immunoblot. We developed an ELISA assay employing recombinant CRT and found elevated serum levels of IgA anti-CRT Ab in 60% and IgG Ab in 80% of these patients. Moreover,in some patients we also found elevated serum IgA Ab to tissue transglutaminase (tTG) and gliadin – serological markers of celiac disease. We would like to: a) measure the levels of IgA and IgG anti-CRT and anti-gliadin Ab and IgA anti-tTG Ab in sera of patients with PT and other oncological patients and in selected risk groups, b) characterize the fine specificity of these Ab, c) study the mechanisms of induction of Ab to CRT and tTG Ab in oncological patients, d) analyse the influence of anti-CRT Ab on tumour cells. (en)
Title	Výskyt, analýza specificity a úloha sérových autoprotilátek proti kalretikulinu a tkáňové transglutamináze u onkologických pacientů a ve vybraných rizikových skupinách (cs) Occurrence, analysis of fine specificity and biological role of serum autoantibodies against calreticulin and tissue transglutaminase in patients with oncological diseases and selected risk groups (en)
http://linked.open...vai/cislo-smlouvy	http://linked.opendata.cz/resource/domain/vavai/cep/smlouva/IAA500200709
http://linked.open...lsi-vedlejsi-obor	http://linked.opendata.cz/resource/domain/vavai/cep/obor/FN
http://linked.open...avai/druh-souteze	http://linked.opendata.cz/resource/domain/vavai/cep/druh-souteze/VS
http://linked.open...domain/vavai/faze	http://linked.opendata.cz/resource/domain/vavai/cep/faze/54084020
http://linked.open...vavai/hlavni-obor	http://linked.opendata.cz/resource/domain/vavai/cep/obor/EC
http://linked.open...vai/vedlejsi-obor	http://linked.opendata.cz/resource/domain/vavai/cep/obor/FD
http://linked.open...vavai/id-aktivity	http://linked.opendata.cz/resource/domain/vavai/cep/aktivita/IA
http://linked.open.../vavai/id-souteze	http://linked.opendata.cz/resource/domain/vavai/cep/soutez/SAV02007-A
http://linked.open...n/vavai/kategorie	http://linked.opendata.cz/resource/domain/vavai/cep/kategorie/1
http://linked.open...vai/klicova-slova	pancreatic tumors; detection of anti-calreticulin autoantibodies; ELISA; recombinant calreticulin; antigenic epitopes; PEPSCAN; role of anti-calreticulin autoantibodies in oncological diseases; screening of celiac disease markers in oncological patient (en)
http://linked.open...avai/konec-reseni	2011-12-31 (xsd:date)
http://linked.open...nujicich-prijemcu	0 (xsd:integer)
http://linked.open...avai/poskytovatel	http://linked.opendata.cz/resource/domain/vavai/cep/poskytovatel/AV0
http://linked.open...avai/start-reseni	2007-01-01 (xsd:date)
http://linked.open...ai/statni-podpora	2857 (xsd:integer)
http://linked.open...vavai/typProjektu	http://linked.opendata.cz/resource/domain/vavai/cep/typ/P
http://linked.open...ai/uznane-naklady	2857 (xsd:integer)
http://linked.open...ai/pocet-prijemcu	1 (xsd:integer)
http://linked.open...cet-spoluprijemcu	0 (xsd:integer)
http://linked.open...ai/pocet-vysledku	7 (xsd:integer)
http://linked.open...ku-zverejnovanych	7 (xsd:integer)
is http://linked.open...ain/vavai/projekt of	http://linked.opendata.cz/resource/domain/vavai/cep/ucast/2007/IAA500200709/ico-61388971 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/2008/IAA500200709/ico-61388971 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/2009/IAA500200709/ico-61388971 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/2010/IAA500200709/ico-61388971 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/2011/IAA500200709/ico-61388971 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/2012/IAA500200709/ico-61388971

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 111 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software